Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
Dr Carla Bauer from Novartis, just posted on LinkedIn she’s leaving her role, post was liked by Fiona McLaughlin? (Note this is pure speculation)
https://www.linkedin.com/in/carla-bauer
It’s back up now with 6000 moving into Phase 2 and 3996 in Phase 1 - not sure what to make of this, except it seems very positive.
https://avacta.com/therapeutics/pipeline/
Is that a new video about Precision on the therapeutics page? https://avacta.com/therapeutics/
Type in “AVA6000” in the find a trial search bar and it returns one result - for another doxorubicin related drug trial addressing sarcoma. Previously I recall getting no search results for “AVA6000”. Does anyone more tech savvy than me know why this would be?
https://www.mskcc.org/cancer-care/clinical-trials/search#q=ava6000&sort=relevancy
Agree there’s no way Avacta would want to buy abdx. Why take the risk of buying a struggling LFT firm which is burning through cash and with the inflationary pressures in the UK. Further its hard to see why Avacta would need to buy any manufacturer when launch diagnostics are making 50% gross margin by contracting out the manufacturing.
Another like from David Brush of Novartis on LinkedIn, head of transactions, business development and licensing. He sure likes Avacta!
https://www.linkedin.com/posts/avacta_oncology-lifescience-cancertherapeutics-activity-6980814881260249088-5v8-?utm_source=share&utm_medium=member_ios
Interesting to see Avacta’s Orphan drug designation post on LinkedIn now liked by David C Brush, head of Transactions, Business Development and Licensing at Novartis Institute for Biomedical research.
He’s an expert in deal making according to his recommendations on LinkedIn.
Novartis are the world’s second largest pharma company…
Interesting to see Blackrock holding doubled in August to nearly 2%. If they keep buying at this pace we could see a TR1.
https://www.morningstar.com/stocks/xlon/avct/ownership
There will be a Series B funding round for Affyxell once the proof-of-concept studies are done. It was mentioned in the preliminary results:
https://avacta.com/preliminary-results-for-the-year-ending-31-december-2021/